Register your Account

Sign Up with us and Enjoy!
User name Email First Name Last Name Contact info

A password will be e-mailed to you.

Top Losers (MOTR, TLAB, ALXA, CERP, KWK)


NEW YORK, December 26, 2012 (MESHPRESS) – PennyStockParlay.com, an investment community with a  special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Motricity Inc(NASDAQ:MOTR) shares decreased 33.35% to $0.440. On December 17, 2012, Motricity received notice from AT&T Mobility LLC that AT&T is terminating the Second Amended and Restated Wireless Service Agreement #0001429 dated July 22, 2005 between the Company and AT&T, as amended, and all services thereunder effective June 30, 2012 pursuant to its right to termination for convenience thereunder.

Should Investors Buy MOTR After The Recent Drop? Find Out Here

Tellabs, Inc.(NASDAQ:TLAB) shares gained 5.22% to $2.62. The company has announced an ex-dividend date of December 24, 2012 and a cash dividend payment of $1 per share scheduled for December 21, 2012. Shareholders who purchased TLAB stock prior to the ex-dividend date are eligible for the cash dividend payment.

We Have Free Trend Analysis on TLAB, Find Out Here

Alexza Pharmaceuticals, Inc.(NASDAQ:ALXA) stock decreased 13.82% to $4.99. The company said the U.S. Food and Drug Administration approved its schizophrenia and bipolar disorder treatment Adasuve. The drug was approved to treat agitation associated with schizophrenia and bipolar disorder in adults, and the company said it is the first noninjectable therapy for the acute treatment of such agitation. The drug is delivered using a hand-held inhaler.

Additionally, ALXA and Grupo Ferrer Internacional SA said the Committee for Medicinal Products for Human Use adopted a positive opinion on recommending European marketing of schizophrenia and bipolar disorder treatment Adasuve, a win for the small drug maker.

Get More latest News, Rumors and Updates On ALXA Here

 

Cereplast, Inc.(NASDAQ:CERP) shares fell 11.30% to $0.0259 in the last trading session. The company announced that Board of Directors has voluntarily decided to move the listing of its common stock from The NASDAQ Capital Market to the OTC Markets’ OTCQB marketplace (“OTCQB”). Cereplast expects that its stock will begin trading on the OTCQB under its ticker symbol “CERP” effective December 17, 2012. Cereplast will file a Form 25 with the Securities and Exchange Commission on December 17, 2012 and cease trading on NASDAQ on December 14, 2012.

How To Trade CERP Now After The Recent Volatile Moves? Find Out Here

Quicksilver Resources Inc(NYSE:KWK) shares dropped 7.96% to $3.12 in the last trading session. Zacks reissued their neutral rating on shares of Quicksilver in a research report released on Dec. 25. Zacks currently has a $3.50 price target on the stock. Additionally, Macquarie upgraded shares of Quicksilver from an underperform rating to a neutral rating in a research note released last month. They currently have $2.50 price target on the stock.

Don’t Forget To Get Your Free Trend Analysis Here

About PennyStockParlay.com
PennyStockParlay.com has been successful in bringing Stock Parlay members with top penny stock newsletter. Stock Parlay’s staff and penny stocks exploration methods have proved 100% accurate in finding the best penny stocks move in e-mail alerts. PennyStockParlay.com works all day and night to find the best penny stock picks portfolio through penny stock newsletter. PennyStockParlay.com has kept winning members with top penny stock newsletter.

Disclaimer:
The assembled information disseminated by PennyStockParlay.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. PennyStockParlay.com does expect that investors will buy and sell securities based on information assembled and presented in PennyStockParlay.com. Please always do due diligence; consult a financial advisor before buying or selling stocks.

Contact Information:
PennyStockParlay.com

Rich Smith
Tel: 2132610916

 

Related Press realease: